{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:03:22Z","timestamp":1790269402518,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier","isbn-type":[{"value":"9780443472169","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002742","name":"Banaras Hindu University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004541","name":"Ministry of Education, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.irn.2026.05.006","type":"book-chapter","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:47:40Z","timestamp":1779709660000},"page":"61-89","source":"Crossref","is-referenced-by-count":0,"title":["Redefining Alzheimer\u2019s disease diagnostics in the age of blood-based biomarkers"],"prefix":"10.1016","author":[{"given":"Pradeep UC","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag TK","family":"Baidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7021-6996","authenticated-orcid":false,"given":"Rajnish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/bs.irn.2026.05.006_bib1","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3390\/medicina61111930","article-title":"Exosomes in clinical laboratory: From biomarker discovery to diagnostic implementation","volume":"61","author":"Aljohani","year":"2025","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/bs.irn.2026.05.006_bib2","article-title":"Clinical utility of an antibody\u2010free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study","volume":"15","author":"Allu\u00e9","year":"2023","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis\u00a0Assessment & Disease Monitoring"},{"key":"10.1016\/bs.irn.2026.05.006_bib3","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s disease facts and figures (2024). Alzheimer\u2019s & Dementia, 20(5), 3708\u20133821.","DOI":"10.1002\/alz.13809"},{"issue":"7","key":"10.1016\/bs.irn.2026.05.006_bib4","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1007\/s00259-021-05253-y","article-title":"The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers","volume":"48","author":"Ashton","year":"2021","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"12","key":"10.1016\/bs.irn.2026.05.006_bib5","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1002\/alz.13455","article-title":"The potential clinical value of plasma biomarkers in Alzheimer\u2019s disease","volume":"19","author":"Blennow","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"9","key":"10.1016\/bs.irn.2026.05.006_bib6","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2026.05.006_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00415-025-13498-y","article-title":"Plasma NfL and GFAP in the preclinical stages of neurodegenerative diseases: Insights from the UK Biobank","volume":"272","author":"Buonocore","year":"2025","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2026.05.006_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1177271920950319","article-title":"Fluid biomarkers for synaptic dysfunction and loss","volume":"15","author":"Camporesi","year":"2020","journal-title":"Biomarker Insights"},{"key":"10.1016\/bs.irn.2026.05.006_bib9","article-title":"Association of plasma p-tau and p-tau\/A\u03b2 ratio with Alzheimer\u2019s pathology","author":"Chen","year":"2026","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jalz.2018.05.006","article-title":"The National Institute on Aging\u2014Alzheimer\u2019s Association Framework on Alzheimer\u2019s disease: Application to clinical trials","volume":"15","author":"Cummings","year":"2019","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"3","key":"10.1016\/bs.irn.2026.05.006_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neurol.2022.09.003","article-title":"Overview of the blood biomarkers in Alzheimer\u2019s disease: Promises and challenges","volume":"179","author":"Delaby","year":"2023","journal-title":"Revue Neurologique"},{"issue":"20","key":"10.1016\/bs.irn.2026.05.006_bib12","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.3390\/ijms252010911","article-title":"Blood-based biomarkers in Alzheimer\u2019s disease: Advancing non-invasive diagnostics and prognostics","volume":"25","author":"Dhauria","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/neu.2013.3040","article-title":"Acute biomarkers of traumatic brain injury: Relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein","volume":"31","author":"Diaz-Arrastia","year":"2014","journal-title":"Journal of Neurotrauma"},{"issue":"3","key":"10.1016\/bs.irn.2026.05.006_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002271","article-title":"Dementia in low-income and middle-income countries: Different realities mandate tailored solutions","volume":"14","author":"Ferri","year":"2017","journal-title":"PLoS Medicine"},{"issue":"8","key":"10.1016\/bs.irn.2026.05.006_bib15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"S2","key":"10.1016\/bs.irn.2026.05.006_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/alz70856_105493","article-title":"Synaptic biomarkers in Alzheimer\u2019s dementia: A meta\u2010analysis","volume":"21","author":"Gaur","year":"2025","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/bs.irn.2026.05.006_bib17","first-page":"1","article-title":"Precision medicine - the golden gate for detection, treatment and prevention of alzheimer\u2019s disease","author":"Hampel","year":"2016","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"5580","key":"10.1016\/bs.irn.2026.05.006_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.irn.2026.05.006_bib19","doi-asserted-by":"crossref","unstructured":"Insights into Biomarkers of Alzheimer\u2019s Disease: From Core Markers to Emerging Directions. (2025). Aging and Disease. https:\/\/doi.org\/10.14336\/AD.2025.0761.","DOI":"10.14336\/AD.2025.0761"},{"issue":"8","key":"10.1016\/bs.irn.2026.05.006_bib20","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"4","key":"10.1016\/bs.irn.2026.05.006_bib21","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/biomedicines12040786","article-title":"Evaluating p-tau217 and p-tau231 as biomarkers for early diagnosis and differentiation of Alzheimer\u2019s disease: A narrative review","volume":"12","author":"Jarek","year":"2024","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/bs.irn.2026.05.006_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70472","article-title":"Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer\u2019s pathogenesis, diagnosis, and insights from non\u2010human primate models","volume":"21","author":"Jin","year":"2025","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/brain\/awad267","article-title":"The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer\u2019s disease","volume":"147","author":"Jung","year":"2024","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2026.05.006_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102481","article-title":"Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: Breaking the memory barrier","volume":"101","author":"Kamatham","year":"2024","journal-title":"Ageing Research Reviews"},{"issue":"11","key":"10.1016\/bs.irn.2026.05.006_bib25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/clinchem\/hvad139","article-title":"Alzheimer disease biomarkers: Moving from CSF to plasma for reliable detection of amyloid and tau pathology","volume":"69","author":"Kang","year":"2023","journal-title":"Clinical Chemistry"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib26","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1038\/s41467-024-47971-5","article-title":"Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases","volume":"15","author":"Karlsson","year":"2024","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/bs.irn.2026.05.006_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders\u2014Towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.irn.2026.05.006_bib28","article-title":"Artificial intelligence for personalized prediction of Alzheimer\u2019s disease progression: A survey of methods, data challenges, and future directions (version 1)","author":"Koksalmis","year":"2025","journal-title":"arXiv"},{"issue":"15","key":"10.1016\/bs.irn.2026.05.006_bib29","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.3390\/ijms25158132","article-title":"Clinical application of blood biomarkers in neurodegenerative diseases present and future perspectives","volume":"25","author":"Krawczuk","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1016\/bs.irn.2026.05.006_bib30","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/biomedicines12081836","article-title":"P-tau217 as a reliable blood-based marker of Alzheimer\u2019s disease","volume":"12","author":"Lai","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41398-020-0801-2","article-title":"Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer\u2019s disease and mild cognitive impairment","volume":"10","author":"Liu","year":"2020","journal-title":"Translational Psychiatry"},{"key":"10.1016\/bs.irn.2026.05.006_bib32","article-title":"Distinct factors drive the progression of tau pathology in Alzheimer\u2019s disease","author":"Luo","year":"2025","journal-title":"Fundamental Research"},{"issue":"5","key":"10.1016\/bs.irn.2026.05.006_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurology"},{"issue":"7691","key":"10.1016\/bs.irn.2026.05.006_bib34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","article-title":"Blood\u2010based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic","volume":"13","author":"O\u2019Bryant","year":"2017","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"17","key":"10.1016\/bs.irn.2026.05.006_bib36","doi-asserted-by":"crossref","first-page":"8564","DOI":"10.3390\/ijms26178564","article-title":"The role of blood-based biomarkers in transforming Alzheimer\u2019s disease research and clinical management: A review","volume":"26","author":"Pacoova Dal Maschio","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.irn.2026.05.006_bib37","doi-asserted-by":"crossref","DOI":"10.1101\/2021.04.11.21255152","article-title":"Plasma glial fibrillary acidic protein is an early marker of A\u03b2 pathology in Alzheimer\u2019s disease","author":"Pereira","year":"2021","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2026.05.006_bib38","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1016\/j.apsb.2025.07.030","article-title":"Artificial intelligence-driven multi-omics approaches in Alzheimer\u2019s disease: Progress, challenges, and future directions","volume":"15","author":"Ren","year":"2025","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/bs.irn.2026.05.006_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1474043","article-title":"Alzheimer\u2019s disease: A comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges","volume":"11","author":"Safiri","year":"2024","journal-title":"Frontiers in Medicine"},{"issue":"7","key":"10.1016\/bs.irn.2026.05.006_bib40","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology\u2014Recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nature Reviews Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2026.05.006_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanhl.2024.07.013","article-title":"Challenges in the practical implementation of blood biomarkers for Alzheimer\u2019s disease","volume":"5","author":"Sch\u00f6ll","year":"2024","journal-title":"The Lancet Healthy Longevity"},{"issue":"4","key":"10.1016\/bs.irn.2026.05.006_bib42","article-title":"Cutting through the noise: A narrative review of Alzheimer\u2019s disease plasma biomarkers for routine clinical use","volume":"12","author":"Sch\u00f6ll","year":"2025","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"10","key":"10.1016\/bs.irn.2026.05.006_bib43","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70377","article-title":"Use of biomarkers in drug development for regulatory purposes","volume":"18","author":"Schuck","year":"2025","journal-title":"Clinical and Translational Science"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Towards clinical implementation","volume":"21","author":"Teunissen","year":"2022","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-Synuclein in the pathophysiology of Alzheimer\u2019s disease","volume":"14","author":"Twohig","year":"2019","journal-title":"Molecular Neurodegeneration"},{"issue":"4","key":"10.1016\/bs.irn.2026.05.006_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102031","article-title":"Cerebrospinal fluid proteomics identification of biomarkers for amyloid and tau PET stages","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Reports Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib47","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13024-019-0317-5","article-title":"Neuronally derived extracellular vesicles: An emerging tool for understanding Alzheimer\u2019s disease","volume":"14","author":"Watson","year":"2019","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/bs.irn.2026.05.006_bib48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ajem.2024.12.005","article-title":"A high-performance core laboratory GFAP\/UCH-L1 test for the prediction of intracranial injury after mild traumatic brain injury","volume":"89","author":"Welch","year":"2025","journal-title":"The American Journal of Emergency Medicine"},{"issue":"8","key":"10.1016\/bs.irn.2026.05.006_bib49","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3390\/pharmaceutics17081041","article-title":"Overcoming the blood\u2013brain barrier: Advanced strategies in targeted drug delivery for neurodegenerative diseases","volume":"17","author":"Yang","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/bs.irn.2026.05.006_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1445479","article-title":"Highly sensitive blood-based biomarkers detection of beta-amyloid and phosphorylated-tau181 for Alzheimer\u2019s disease","volume":"15","author":"Yang","year":"2024","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2026.05.006_bib51","series-title":"Introduction to molecular neurosciences","first-page":"112","article-title":"Blood-based molecular biomarkers for Alzheimer\u2019s disease","author":"Zetterberg","year":"2019"},{"issue":"1","key":"10.1016\/bs.irn.2026.05.006_bib52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"}],"container-title":["International Review of Neurobiology","Blood-Based Biomarkers for Alzheimers and Parkinsons Disease - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774226000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774226000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:22:03Z","timestamp":1790266923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774226000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443472169"],"references-count":52,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2026.05.006","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}